Galderma Shareholders Back Board Refresh and Dividend Policy
Event summary
- Shareholders approved a CHF 0.35 dividend per share from capital reserves, tax-free under Swiss regulations.
- Harry Kirsch elected as independent board member; L’Oréal representatives Samuel du Retail and Delphine Viguier-Hovasse added as non-independent directors.
- Existing board members Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy, and Dr. Flemming Ørnskov re-elected.
- 2025 financial statements, non-financial report, and compensation report all ratified.
The big picture
Galderma’s AGM approvals reflect a balance between shareholder returns and governance adjustments tied to L’Oréal’s stake. The dermatology sector’s rapid growth—driven by aesthetics and therapeutic innovation—demands board agility, particularly as Galderma navigates its position as a pure-play leader in a consolidating market.
What we're watching
- Board Dynamics
- How L’Oréal’s increased board representation will influence Galderma’s strategic direction, given its role as a minority shareholder.
- Dividend Sustainability
- Whether the CHF 0.35 payout can be maintained amid dermatology market volatility and R&D investment needs.
- Regulatory Compliance
- The pace at which Swiss tax policies may evolve, affecting future dividend structures for Galderma.